Pfizer Inc CDR

Pfizer Inc CDR

PFE · NEO · Healthcare / Drug Manufacturers - General

12.75CAD-0.04 (-0.31%)

Price History

Full chart

Market Stats

Previous Close12.79
Open12.82
Day Range12.72 – 12.82
52-Week Range10.25 – 13.00
Volume12.90K
Market Cap214.61B
P/E (TTM)15.43
Forward P/E8.96
EPS0.80
Dividend Yield6.79%
Beta0.42
50-Day Avg11.42
200-Day Avg11.19

About

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular and migraine under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, Octagam, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak, and Talzenna brands. In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Company Details

  • SectorHealthcare
  • IndustryDrug Manufacturers - General
  • CEODr. Albert Bourla D.V.M., Ph.D.
  • Employees81.00K
  • Headquarters66 Hudson Boulevard East, New York, NY, United States, 10001-2192, Canada
  • Websitehttps://www.pfizer.com

Leadership

  • Dr. Albert Bourla D.V.M., Ph.D.Chairman of the Board & CEO · b. 1962
  • Mr. David M. DentonExecutive VP & CFO · b. 1965
  • Dr. Chris Boshoff FMedSci, M.D., Ph.D.Chief Scientific Officer and President of Research & Development · b. 1964
  • Mr. Aamir MalikExecutive VP & Chief U.S. Commercial Officer · b. 1976
  • Ms. Jennifer B. DamicoSenior VP, Controller & Principal Accounting Officer · b. 1968
  • Ms. Lidia L. FonsecaExecutive VP and Chief Digital & Technology Officer · b. 1969
  • Ms. Francesca M. DeMartinoChief Investor Relations Officer
  • Mr. Douglas M. LanklerExecutive VP & Chief Legal Officer · b. 1966
  • Ms. Payal Sahni BecherChief People Experience Officer & Executive VP · b. 1975
  • Ms. Sally M. SusmanExecutive VP & Chief Corporate Affairs Officer · b. 1962

Financials

Income Statement

Currency: USD2018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue53.65B51.75B41.91B81.29B100.33B59.55B63.63B62.58B
Growth (%)--3.54%-19.02%+93.97%+23.43%-40.64%+6.84%-1.65%
Cost of Revenue11.25B10.22B8.69B30.82B34.34B24.95B17.85B16.07B
Gross Profit42.40B41.53B33.22B50.47B65.99B34.60B45.78B46.51B
Gross Margin79.03%80.25%79.26%62.08%65.77%58.10%71.94%74.33%
Operating Expense27.35B27.61B24.46B30.23B28.71B30.18B30.84B29.11B
Operating Income15.04B13.92B8.76B20.23B37.27B4.42B14.94B17.41B
Operating Margin28.04%26.90%20.90%24.89%37.15%7.42%23.48%27.82%
EBITDA19.59B25.27B13.72B30.79B39.58B9.56B18.13B16.78B
EBITDA Margin36.51%48.82%32.75%37.88%39.45%16.05%28.49%26.82%
Net Income11.15B16.27B9.62B21.98B31.37B2.12B8.03B7.77B
Net Income Margin20.79%31.45%22.95%27.04%31.27%3.56%12.62%12.42%
R&D8.01B8.65B9.40B13.83B11.43B10.68B10.82B10.44B
R&D as % of Total Revenue14.92%16.71%22.44%17.01%11.39%17.93%17.01%16.68%
Interest Expense1.32B1.57B1.45B1.29B1.24B2.21B3.09B2.67B
Interest Expense % of Total Revenue2.45%3.04%3.46%1.59%1.23%3.71%4.86%4.27%

Balance Sheet

Currency: USD2018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets159.42B167.49B154.23B181.48B197.21B226.50B213.40B208.16B
Total Liabilities95.66B104.04B90.76B104.01B101.29B137.21B124.90B121.39B
Total Equity63.41B63.14B63.24B77.20B95.66B89.01B88.20B86.48B
Cash1.14B1.30B1.78B1.94B416.00M2.85B1.04B1.14B
Net Debt40.13B50.84B36.49B35.05B34.45B67.99B62.61B62.82B

Cash Flow

Currency: USD2018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow15.83B12.59B14.40B32.58B29.27B12.04B12.74B11.70B
Investing Cash Flow4.53B-3.94B-4.27B-22.55B-15.78B---
Financing Cash Flow-20.44B-8.48B-9.65B-9.82B-14.83B15.61B-17.14B-10.30B
Capital Expenditure1.98B2.05B2.23B2.71B3.24B3.86B2.91B2.63B
Free Cash Flow13.63B9.99B11.61B29.87B26.03B8.18B9.84B9.07B
Dividends Paid7.98B8.04B8.44B8.73B8.98B9.18B9.51B9.77B
FCF to OCF86.12%79.39%80.62%91.68%88.94%67.91%77.17%77.54%
Dividend Paid to FCF58.53%80.48%72.68%29.22%34.51%112.22%96.72%107.67%

Key Statistics & Ratios

Market Cap214.61B
Enterprise Value295.68B
Trailing P/E15.43
Forward P/E8.96
PEG Ratio11.94
Price / Sales3.42
Price / Book1.75
EPS0.80
Book Value22.49
Revenue (TTM)62.78B
Gross Profit (TTM)46.97B
EBITDA24.46B
Profit Margin15.65%
Operating Margin35.28%
Return on Equity10.60%
Return on Assets5.19%
Shares Outstanding16.74B
Shares Float5.68B
Beta0.42
Dividend Yield6.79%
Dividend Rate0.78
Payout Ratio95.87%

Dividends

20264×
0.19Nov 6, 20260.19Jul 24, 20260.20May 8, 20260.19Jan 23, 2026
20254×
0.19Nov 7, 20250.20Jul 25, 20250.19May 9, 20250.20Jan 24, 2025
20244×
0.20Nov 8, 20240.19Jul 26, 20240.20May 9, 20240.20Jan 25, 2024
20234×
0.19Nov 9, 20230.20Jul 27, 20230.19May 11, 20230.20Jan 26, 2023
20224×
0.19Nov 3, 20220.19Jul 28, 20220.19May 12, 20220.19Jan 27, 2022